InTandem Capital Partners Closes Healthcare Fund at $715M
Healthcare-focused private equity firm InTandem Capital Partners held the final close of its third fund, InTandem Capital Partners Fund III, with $715 million in total capital commitments and above its original target of $650 million.
The latest fund is nearly 3X the size of the firm’s sophomore fund, which closed at $250 million in 2019. The New York-based firm previously raised $175 million for its maiden fund in 2017 and amassed $225 million for an opportunities fund in 2022.
The fund will continue the firm’s strategy of making control investments in North American payor, provider, and pharmaceutical services businesses.
The fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organization focused on late-stage outpatient central nervous system trials.
“Our long-standing focus on the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery – continues to resonate with institutional investors,” added Brad Coppens, senior partner of InTandem.